A Prospective Trial of a Bio-absorbable Mesh in Challenging Laparoscopic Ventral or Incisional Hernia Repair

Not Applicable

Completed

Conditions: Hernia, Ventral
Incisional Hernia

Interventions: Device: Phasix™ ST

Registration Number: NCT02712398

Lead Sponsor: C. R. Bard

Brief Summary: The objective of this study is to collect additional data on safety, performance and effectiveness of Phasix™ ST in subjects receiving laparoscopic ventral or incisional hernia repair at high risk for surgical site occurrence (SSO).

Detailed Description: Subjects at high risk are defined as having 1 or more of the following co-morbid conditions: body mass index (BMI) between 30-40 kg/m2, inclusive, active smokers, chronic obstructive pulmonary disease (COPD), diabetes, immunosuppression, coronary artery disease, chronic corticosteroid use, low pre-operative serum albumin, advanced age, or renal insufficiency.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 120

Inclusion Criteria

Subject must be 18 years of age or older
Subject must be willing to give written informed consent
Subject must be diagnosed with ventral or abdominal incisional hernia
Subject must be willing to undergo laparoscopic hernia repair using intraabdominal placement (with or without Component Separation Technique (CST))
Surgeon must be able to fully close the hernia defect. Defect closure is defined as complete reapproximation of fascial edges, leaving no gap. Since the safety and effectiveness of Phasix™ ST Mesh in bridging repairs has not been evaluated or established, the defect should be closed prior to mesh use.
Subject is expected to meet the criteria for a Class I wound
Subjects must have 1 or more of the following pre-study conditions:
1. Body Mass Index (BMI) between 30-40 kg/m2, inclusive
2. Active smoker (including if attempts to quit smoking within two weeks of surgery have failed and the patient is still an active smoker at the time of surgery)
3. COPD presence on patient self-report
4. Diabetes mellitus (if yes, diagnosis to be confirmed via medical records or laboratory results according to 2014 Joslin Clinical Guideline for Adults with Diabetes)(Appendix 5)
5. Immunosuppression
6. Coronary Artery Disease
7. Chronic corticosteroid use: greater than 6 months systemic use
8. Serum albumin less than 3.4 g/dL
9. Advanced age: 75 years or older
10. Renal insufficiency, defined as serum creatinine concentration ≥2.5 mg/dL

Exclusion Criteria

Subject has had 4 or more previous hernia repairs (of the index hernia)
Subject's hernia is > 350 cm2
Complete removal of existing mesh from a prior hernia repair (in the same affected area) is not possible
Subject has intact permanent mesh adjacent to the current hernia to be repaired
Preperitoneal placement of mesh
The subject is known to have a collagen disorder
The subject has peritonitis
The subject is on or suspected to be placed on chemotherapy medications during any part of the study
The subject's Body Mass Index (BMI) is > 40 kg/m2
The subject has cirrhosis of the liver and/or ascites
Subject is American Society of Anesthesiology Class 4 or 5
Subject has a life expectancy of less than 2 years at the time of enrollment
Subject has any condition that, in the opinion of the Investigator, would preclude the use of the study device, or preclude the subject from completing the follow-up requirements
Subject has a surgical wound classified as Class II (Clean-Contaminated), Class III (Contaminated) or Class IV (Dirty-Contaminated)
Subject has an active or latent systemic infection
Patient has a contraindication to placement of mesh
Subject requires surgical bridge repair as the sole repair
Subject is pregnant or has plans to become pregnant during the study period
Subject has enrolled in another interventional clinical study within the last 30 days
Subject is part of the site personnel directly involved with this study
Subject has a known allergy to the test device or component materials (patients with known allergies to tetracycline hydrochloride or kanamycin sulfate should be avoided).

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Phasix™ ST	Phasix™ ST	Subjects treated with Phasix™ ST mesh

Primary Outcome Measures

Name	Time	Method
Surgical Site Occurrence Rate	45 Days	Proportion of subjects with Surgical Site Occurrences(SSO), which are defined as hematoma, seroma, surgical site infection, wound dehiscence, skin necrosis and fistula requiring intervention. Occurrences at the surgical site will be assessed by physical examination at each study visit through 45 days.

Secondary Outcome Measures

Name	Time	Method
Surgical Site Occurrence Rate	3 months	Number of subjects with Surgical Site Occurrences, which are defined as hematoma, seroma, surgical site infection, wound dehiscence, skin necrosis and fistula requiring intervention. Occurrences at the surgical site will be assessed by physical examination at each study visit through 3 months.
Hernia Recurrence Rate	24 Months	Proportion of subjects with hernia recurrence. Hernia recurrence rates will be assessed by physical examination (or if standard of care via CT/MRI or ultrasonography) at each study visit through 24 months. A recurrent hernia will be defined as any hernia identified or confirmed by the investigator, during any study follow-up visit, in approximately the same position as the hernia repaired in the study procedure.
Pain Visual Analog Scale	24 Months	Mean change in self-reported pain measured on a Visual Analog Scale between Baseline and 24-month through follow up. Scores are measured on a 10.0 cm line, scores range from 0 to 10, higher values correspond with higher pain perception. The outcome measure is presented as the absolute difference between the pain perception at Baseline and the pain perception at 24-month follow up.
Device-related Adverse Event Incidence	24 Months	Proportion of subjects with Investigator-determined device-related adverse events
Rate of Reoperation Due to Index Hernia Repair	24 Months	Rate of reoperation due to the index hernia repair
Change in Carolinas Comfort Scale	24 Months	Each scale score (sensation of mesh, pain or movement limitations) ranges from 0-5 and is the average across the domains. The Total CCS Score ranges from 0-5 and is the average of the 3 scale scores. Low scores represent fewer symptoms or difficulties. Absolute values of the Total CCS Score at Baseline, 1-Month follow-up, at 3-Month follow-up, at 6-Month follow-up, at 12-Month follow-up, at 18-Month follow-up, and at 24-Month follow up are reported. The absolute value at Baseline, or a change in self-reported quality of life measured by Carolinas Comfort Scale® cannot be reported, as subjects had incorrectly answered the questions on Sensation of Mesh at Baseline where no Phasix Mesh was yet implanted, thereby creating a bias in the results.
Change in SF(Short-form)-12	24 Months	The Short Form (SF)-12 version 2 (v2) is a multi-purpose, twelve item health survey that measures seven domains of health: general health, physical functioning, role limitations due to physical health (role-physical), role limitations due to emotional problems (role-emotional), bodily pain, vitality and mental health and social functioning. The SF-12v2 yields scale scores for each of these seven health domains, and two summary measures of physical and mental health: the physical component summary (PCS) and mental component summary (MCS). The scores range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health. Absolute values of the PCS and MCS scores at Baseline, 1-Month follow-up, at 3-Month follow-up, at 6-Month follow-up, at 12-Month follow-up, at 18-Month follow-up, and at 24-Month follow up are reported.
Surgical Procedure Time as Measured From Incision to Closure	During Procedure, up to 243 minutes	Surgical procedure time as measured from incision to closure (skin to skin)
Length of Hospital Stay	1 month	Number of days admitted to the hospital for index surgery

Trial Locations

Locations (16): Hershey Penn State Medical Center
🇺🇸
Hershey, Pennsylvania, United States
Carilion Clinic
🇺🇸
Roanoke, Virginia, United States
Memorial Health University Medical Center
🇺🇸
Savannah, Georgia, United States
University of Wisconsin
🇺🇸
Madison, Wisconsin, United States
Overlake Hospital
🇺🇸
Bellevue, Washington, United States
Yale-New Haven Medical Center
🇺🇸
New Haven, Connecticut, United States
Via-Christi Hospital
🇺🇸
Wichita, Kansas, United States
University of Kentucky Medical Center
🇺🇸
Lexington, Kentucky, United States
Methodist Hospital
🇺🇸
Omaha, Nebraska, United States
New Hanover Regional Medical Center
🇺🇸
Wilmington, North Carolina, United States
Our Lady of the Lake Regional Medical Center
🇺🇸
Baton Rouge, Louisiana, United States
Florida Hospital
🇺🇸
Celebration, Florida, United States
Emory University
🇺🇸
Atlanta, Georgia, United States
Washington University
🇺🇸
Saint Louis, Missouri, United States
Georgetown Community Hospital
🇺🇸
Georgetown, Kentucky, United States
Legacy Emanuel Hospital
🇺🇸
Portland, Oregon, United States